(0.09%) 5 308.13 points
(-0.49%) 39 807 points
(0.65%) 16 795 points
(-0.60%) $79.32
(-0.51%) $2.74
(-0.88%) $2 417.00
(-2.52%) $31.61
(-1.98%) $1 042.60
(0.02%) $0.921
(0.25%) $10.72
(-0.01%) $0.787
(0.02%) $90.70
@ $0.740
Utstedt: 13 feb 2024 @ 18:37
Avkastning: 1 346.14%
Forrige signal: feb 13 - 17:13
Forrige signal:
Avkastning: 0.58 %
Live Chart Being Loaded With Signals
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies...
Stats | |
---|---|
Dagens volum | 285 119 |
Gjennomsnittsvolum | 740 439 |
Markedsverdi | 224.69M |
EPS | $0 ( 2024-05-14 ) |
Neste inntjeningsdato | ( $0 ) 2024-08-06 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 0.920 |
ATR14 | $0.0320 (0.30%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-17 | Armen Garo H | Buy | 1 502 | Common Stock |
2024-05-03 | Armen Garo H | Buy | 1 248 | Common Stock |
2024-02-05 | Hirsch Susan B | Buy | 5 000 | Stock Option |
2024-02-05 | Wiinberg Ulf | Buy | 5 000 | Stock Option |
2024-02-05 | Corvese Brian | Buy | 15 000 | Stock Option |
INSIDER POWER |
---|
100.00 |
Last 98 transactions |
Buy: 11 171 341 | Sell: 367 647 |
Volum Korrelasjon
Agenus Inc Korrelasjon
10 Mest positive korrelasjoner | |
---|---|
HNVR | 0.838 |
10 Mest negative korrelasjoner |
---|
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Agenus Inc Korrelasjon - Valuta/Råvare
Agenus Inc Økonomi
Annual | 2023 |
Omsetning: | $156.31M |
Bruttogevinst: | $139.62M (89.32 %) |
EPS: | $-13.73 |
FY | 2023 |
Omsetning: | $156.31M |
Bruttogevinst: | $139.62M (89.32 %) |
EPS: | $-13.73 |
FY | 2022 |
Omsetning: | $98.02M |
Bruttogevinst: | $-99.24M (-101.24 %) |
EPS: | $-0.960 |
FY | 2021 |
Omsetning: | $295.67M |
Bruttogevinst: | $113.59M (38.42 %) |
EPS: | $-0.110 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Agenus Inc
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, the company develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS, as well as in clinical stage to treat hematological malignancies and multiple myeloma/B cells; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. operates under ASV, Agenus, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.